The Dog Cancer Survival Guide (137 page)

Evaluation of the effect of levamisole and surgery on canine mammary cancer. MacEwen EG, Harvey HJ, Patnaik AK, et al.
J Biol Resp Mod
25:540, 1985.

Mammary tumor recurrence in bitches after regional mastectomy. Stratmann N, Failing K, Richter A, et al.
Vet Surg
37(1):82, 2008.

Prognostic factors associated with survival two years after surgery in dogs with malignant mammary tumors: 79 cases (1998-2002). Chang S, Chang C, Chang T, Wong M.
J Am Vet
Med Assoc
227:1625, 2005.

Massage and Touch Therapies

Safety and efficacy of massage therapy for patients with cancer. Corbin L.
Cancer Control.
2005 Jul;12(3):158-64. Review.

Massage Therapy vs. Simple Touch to Improve Pain and Mood in Patients with Advanced Cancer:A Randomized Trial, Kutner, JS et al.
Ann Intern Med.
2008 September 16; 149(6):369–379.

Massage therapy for symptom control: outcome study at a major cancer center. Cassileth BR and Vickers AJ.
J Pain Symptom Manage
. 2004 Sep;28(3):244-9.

WITHDRAWN: Aromatherapy and massage for symptom relief in patients with cancer. Fellowes D, Barnes K, Wilkinson SS.
Cochrane Database Syst Rev
. 2008 Oct 8;(4)

The effect of massage on immune function and stress in women with breast cancer--a randomized controlled trial. Billhult A, et al.
Auton Neurosci
. 2009 Oct 5;150(1-2):111-5.

Role of massage therapy in cancer care. Russell NC, et al.
J Altern Complement Med
. 2008 Mar;14(2):209-14.

Impact of massage therapy on anxiety levels in patients undergoing radiation therapy: randomized controlled trial. Campeau MP, et al.
J Soc Integr Oncol
. 2007 Fall;5(4):133-8.

The use of therapeutic massage as a nursing intervention to modify anxiety and the perception of cancer pain. Ferrell-Torry AT, Glick OJ.
Cancer Nurs
. 1993 Apr;16(2):93-101.

Efficacy of complementary and alternative medicine therapies in relieving cancer pain: a systematic review. Bardia A, et al.
J Clin Oncol
. 2006 Dec 1;24(34):5457-64.

Safety and efficacy of massage therapy for patients with cancer. Corbin L.
Cancer Control.
2005 Jul;12(3):158-64.

Mast Cell Tumors

Mast Cell Tumors. McCaw DL, in Henry CJ, Higginbotham ML (ed):
Cancer Management in Small Animal Practice
. Missouri. Saunders Elsevier 2010, p 317-321.

Mast cell tumors. Thamm DH, Vail DM, in Withrow SJ, Vail DM (eds):
Withrow & MacEwen’s Small Animal Clinical Oncology
. Missouri, Saunders Elsevier, 2007, pp 402-424.

Mast cell tumors, Dog, Geiger T, in Cote E (2
^nd
ed),
Clinical Veterinary Advisor: Dogs and Cats
. Missouri, Mosby Elsevier, 2011, p 701-703.

Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Patnaik AK, Ehler WJ, MacEwen EG.
Vet Pathol.
21:469-74. 1984

Biologic behavior and prognostic factors for mast cell tumors of the canine muzzle: 24 cases (1990-2001). Gieger TL, Théon AP, Werner JA, et al.
J Vet Intern Med.
17:687.2003

Mitotic index is predictive for survival for canine cutaneous mast cell tumors. Romansik EM, Reilly DM, Moore PF, et al.
Vet Pathol
44:355, 2007.

Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004). Mullins MN, Dernell WS, Withrow SJ, et al.
J Am Vet Med Assoc
228:91, 2000.

Canine mastocytoma: excess risk as related to ancestry. Peters JA.
J Natl Cancer Inst
42:435, 1969.

Proposal of a 2-Tier Histologic Grading System for Canine Cutaneous Mast Cell Tumors to More Accurately Predict Biological Behavior. Kiupel M, Webster JD, Bailey KL, et al.
Vet Pathol
48:147-155, 2011.

Mast Cell Treatment

Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs
.
Fulcher RP, Ludwig LL, Bergman PJ, et al.
J Am Vet Med Assoc.
228:210. 2006.

Radiotherapy of incompletely resected, moderately differentiated mast cell tumors in the dog: 37 cases (1989-1993). Frimberger AE, Moore AS, LaRue SM, et al.
J Am Anim Hosp Assoc
. 33(4):320. 1997

A prospective study of radiation therapy for the treatment of grade 2 mast cell tumors in 32 dogs. al-Sarraf R, Mauldin GN, Patnaik AK et al.
J Vet Intern Med.
10:376. 1996

Treatment of canine mast cell tumours with prednisolone and radiotherapy. Dobson J, Cohen S, Gould S.
Vet Comp Oncol.
2:132. 2004

Efficacy of radiation therapy for incompletely resected grade III MCT in dogs: 31 cases. Hahn KA, King GK, Carrera JK.
J Am Vet Med Assoc
. 224:79, 2004.

Melanoma

Oral and Salivary Gland Tumors. Henry CJ, Higginbotham ML, in Henry CJ, Higginbotham ML (ed):
Cancer Management in Small Animal Practice
. Missouri. Saunders Elsevier 2010, p 195-203.

Tumors of the Skin, Subcutis and other soft tissues. Northrup N, Geiger T, in Henry CJ, Higginbotham ML (ed):
Cancer Management in Small Animal Practice
. Missouri. Saunders Elsevier 2010, p 299-311.

Oral Tumors. Liptak JM, Withrow SJ. Withrow SJ, Vail DM (eds):
Withrow & MacEwen’s Small Animal Clinical Oncology
. Missouri, Saunders Elsevier, 2007, pp 455-475

Melanomain. Proulx DR. Cote E (2
^nd
ed),
Clinical Veterinary Advisor: Dogs and Cats
. Missouri, Mosby Elsevier, 2011, p 711- 713.

Multimodality therapy for head and neck cancer. Klein MK.
Vet Clin Small Anim
33:615-628, 2003.

Tumors of the Skin and Subcutaneous tissues. Vail DM, Withrow SJ. Withrow SJ, Vail DM (eds):
Withrow & MacEwen’s Small Animal Clinical Oncology
. Missouri, Saunders Elsevier, 2007, pp 375-401

Tumors of the Nasal Cavity and Paranasal Sinuses, Nasopharynx, Oral Cavity, and Oropharynx. Schantz SP, Harrison LB, Forastiere AA, in Devita VT, Hellman A, Rosenberg SA (ed.):
Cancer Principles & Practice of Oncology.
NY. Lippincott Williams & Wilkens, 2001. p 797-860

Oral cavity risk factors: experts’ opinions and literature support. Stucken E, Weissman J, Spiegel JH.
J Otolaryngol Head Neck Surg.
39(1): 76-89. 2010

Body Mass Index, Cigarette Smoking, and Alcohol Consumption and Cancers of the Oral Cavity, Pharynx, and Larynx: Modeling Odds Ratios in Pooled Case-Control Data. Lubin JH, Gaudet MM, Olshan AF, et al.
Am J Epidemiol.
2010 May 21. [Epub ahead of print]

Association between lymph node size and metastasis in dogs with oral malignant melanoma: 100 cases (1987-2001). Williams LE, Packer RA.
J Am Vet Med Assoc
222:1234, 2003.

Sensitivity and specificity of methods of assessing the regional lymph nodes for evidence of metastasis in dogs and cats with solid tumors. Lagenbach A, McManus PM, Hendrick MJ, et al.
J Am Vet Med Assoc
218:1424, 2001.

The molecular basis of canine melanoma: pathogenesis and trends in diagnosis and therapy. Modiano JF, Ritt MG, Wojcieszyn J.
J Vet Intern Med
13:163, 1999.

Histologic features and clinical outcomes of melanomas of lip, haired skin, and nail bed location of dogs. Schultheiss PC.
J Vet Diagn Invest
18(4): 422, 2006.

Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases. Ramos-Vara, JA, Miller MA, Beissenherz ME, et al.
Vet Pathol
37:597, 2000

Histologic features and clinical outcomes of melanomas of lip, haired skin, and nail bed location of dogs. Schultheiss PC.
J Vet Diagn Invest
18(4):422, 2006.

Oral Melanoma Treatment

Prognosis after surgical excision of canine melanomas. Bostock DE.
Vet Pathol
16:32, 1979

Owner satisfaction with partial mandibulectomy or maxillectomy for treatment of oral tumors in 27 dogs. Fox LE, Geoghegan SL, Davis LH, et al.
J Am Anim Hosp Assoc
33:25, 1997

A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation
.
Proulx DR, Ruslander DM, Dodge RK, et al.
Vet Radiol Ultrasound.
44(3):352-9. 2003

Radiotherapy of oral malignant melanomas in dogs. Blackwood L, Dobson JM.
J Am Vet Med Assoc
209:98, 1996

Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987- 1997). Freeman KP, Hahn KA, Harris FD, et al.
J Vet Int Med
17:96, 2003.

Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). Rassnick KM, Ruslander DM, Cotter SM et al.
J Am Vet Med Assoc.
218(9):1444-8. 2001

Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Bergman PJ, et al.
Vaccine
24:4582-4585. 2006

Long-Term Survival of Dogs with Advanced Malignant Melanoma after DNA Vaccination with Xenogeneic Human Tyrosinase: A Phase I Trial. Bergman PJ, et al.
Clinical Cancer Research
9:1284-1290. 2003

Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Liao JCF, et al.
Cancer Immunity
6:8-17. 2006

Retrospective evaluation of lingual tumors in 42 dogs: 1999- 2005. Syrcle JA, Bonczynski JJ, Monette S, et al.
J Am Anim Hosp Assoc
44:308, 2008.

Digit Melanoma Treatment

Xenogeneic Murine Tyrosinase DNA Vaccine for Malignant Melanoma of the Digit is Dogs
.
Manley CA, Leibman NF, Wolchok JD, et al.
J Vet Int Med
25:94, 2011.

Evaluation of dogs with digit masses: 117 cases (1981-1991). Marino DJ, Matthiesen DT, Stefanacci JD, et al.
J Am Vet Med Assoc.
207(6):726-8. 1995

Canine digital tumors: a veterinary cooperative oncology group retrospective study of 64 dogs. Henry CJ, Brewer WG, Whitley EM, et al.
J Vet Intern Med
19:720, 2005

Skin Melanoma Treatment

Muller and Kirk’s small animal dermatology
, ed 5. Scott DW, Miller WH, Griffin CE. Philadelphia, 1995, WB Saunders.

A comparative review of melanocytic neoplasms. Smith SH, Goldschmidt MH, McManus PM.
Vet Pathol
39:651, 2002.

Characteristics of canine melanomas and comparison of histology and DNA ploidy to their biologic behavior. Bolon B, Calderwood Mays MB, Hall BJ.
Vet Pathol
. 27(2):96-102. 1990

PCNA and Ki- 67 proliferation markers as criteria for prediction of clinical behaviour of melanocytic tumours in cats and dogs. Roels S, Tilmant K, Ducatelle R.
J Comp Pathol.
121(1):13-24. 1999

Modified Citrus Pectin

Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Glinsky VV, Raz A.
Carbohydr Res
. 2009 Sep 28;344(14):1788-91. Epub 2008 Sep 26. Review.

Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. Nangia-Makker P, et al.
J Natl Cancer Inst
. 2002 Dec 18;94(24):1854-62.

Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. Pienta KJ, et al.
J Natl Cancer Inst.
1995 Mar 1;87(5):348-53.

Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. Liu HY, Huang ZL, Yang GH, Lu WQ, Yu NR.
World J Gastroenterol.
2008 Dec 28;14(48):7386-91.

Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Guess BW, Scholz MC, Strum SB, Lam RY, Johnson HJ, Jennrich RI.
Prostate Cancer Prostatic Dis.
2003;6(4):301-4.

Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. Markowska AI, Liu FT, Panjwani N.
J Exp Med.
2010 Aug 30;207(9):1981-93.

PectaSol-C modified citrus pectin induces apoptosis and inhibition of proliferation in human and mouse androgen-dependent and- independent prostate cancer cells. Yan J, Katz A.
Integr Cancer Ther
. 2010 Jun;9(2):197-203.